Find Out How Cybin Inc. (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) is Poised to Lead What Could Easily Become a Multi-Trillion Dollar Mental Health Treatment Revolution

Love him or hate him, Elon Musk has become a major voice in the investment community. Many would even go so far as to say he has replaced Warren Buffett as the market’s true oracle.

Whether you believe that or not, Musk’s proclamations certainly draw attention and spark thought. So when Musk posted the following tweet recently, investor interest in the psychedelics sector skyrocketed. Here’s the tweet:

It turns out science has revealed very positive early-stage results using psychedelic substances like psilocybin, DMT and MDMA to treat multiple mental disorders. How positive? The treatments may be as much as 4 times more effective than what has been used in the past, results indicate.1

That’s a big reason why the amount of money venture capitalists are pouring into the market skyrocketed by 500% between 2016 and 2021!2

2

As this marketplace explodes in size, one company to keep an eye on is Cybin Inc. (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN), which was named “The Psychedelics Company of the Year” in 2021 and which is aiming to beat Musk at his own game through a unique partnership that it recently formed.

Cybin’s Partnership With Kernel Offers Alternative to Musk’s Neuralink

Musk’s interest in the biopharma space has led him to help launch a company called Neuralink, which is seeking to create “ultra high bandwidth brain-machine interfaces to connect humans and computers.”3

To ultimately accomplish this mission, Neuralink would drill holes in people’s skulls to implant microchips in their brains.

However, there’s another company called Kernel, led by American entrepreneur, venture capitalist, writer and author Bryan Johnson, that’s seeking to create brain-machine interfaces through noninvasive means (a helmet).

Kernel’s helmet, in addition to basically being able to read people’s minds, could also provide valuable insight into various brain conditions like brain aging, mental disorders and more.

Johnson, who made his fortune in payment processing, is a leader of the quantified-self movement. It has been reported that he has had every cell in his body repeatedly analyzed and treated by doctors. Those doctors now say tests indicate his body is a full 10 years younger than his age of 43. Johnson wants others to be able to perfect their bodies and minds as well, which has led to the creation of his helmets, which carry a price of $50,000 each.

It’s also why Cybin Inc. (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) and Kernel have partnered to conduct a first-of-its-kind study on the effects of psychedelics on the brain using Kernel’s helmet technology. 

The study results, Kernel’s technology and Cybin’s psychedelic treatments could all be “game-changing.” So let’s learn more about this potential breakout company.

The Little-Known Company That Could Lead a Multi-TRILLION-Dollar Revolution

Cybin Inc. (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) also just partnered with The Chopra Foundation4 to increase education and awareness about the potential use of psychedelic therapies in mental health.

Not only that, BlackRock, the largest asset manager in the world with roughly $9.5 trillion in AUM, also just took a $1 million position in Cybin Inc. (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN)5

That’s why we’re so excited about Cybin and psychedelics… this could be like the early days of cannabis investing!

6

The Marijuana Single-Year Surge & What the Coming Psychedelic Boom Could Potentially Look Like

Many missed out on the cannabis surge because they couldn’t look past the surface-level controversy.

But the fact is, many profitable breakthroughs today were once controversial:

  • Electric cars
  • Crypto
  • Gambling

… and in health, there are stem cells, gene editing, and vaccines.

See what we mean?

And many who had the foresight to invest in these industries ended up making good money, especially if they picked the right opportunities in the right space.

This is why you’re learning about Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN), because it recently won the award:

"Psychedelic Company of the Year in 2021!”

Cybin has secured one of the best financial positions in the space since it’s raised over $120M so far.7

And had cash and equivalents of $63.6 million at the end of last year.8

Why is Cybin Inc. (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) in such a strong position?

Because this biopharmaceutical company already has footholds in Canada… the United States… Ireland… and the United Kingdom.9

Using psychedelics, they approach this new era of mental health in a way no one else does.

You see, classic psychedelic molecules have shown positive efficacy, but have significant limitations like: slow onset of action, extended duration of effect, and a variability in response among patients.

Cybin’s proprietary new chemical entities retain the benefits and address the challenges of classic psychedelic molecules and have shown less patient variability, faster onset of action, shorter duration of effect and improved brain penetration.

Cybin is turning psychedelics into therapeutics.

Cybin’s research and development pipeline and lead molecule programs are targeting Major Depressive Disorder (Molecule CYB003), Alcohol Use Disorder (Molecule CYB003), Anxiety Disorders (Molecule CYB004) and Neuroinflammation (Molecule CYB005).

The company just submitted an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for CYB003, making it the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder. 

“Following the successful completion of our IND-enabling work just last month, we are very excited to have reached this major milestone toward advancing CYB003 into clinical development so quickly,” said Doug Drysdale, Chief Executive Officer of Cybin.

Why “Smart Money” Could Continue Pouring Into Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN)

Reason #1 – The Psychedelic Medicine Market Has Reached an "Inflection Point"

The psychedelic space has attracted several notable celebrities, athletes and investors like PayPal founder Peter Thiel, two-time Stanley Cup Champion Daniel Carcillo and Mike Tyson.

Even Shark Tank’s Kevin O’ Leary got in on psychedelics and believes it “is a brand-new area of medicine with such incredible potential.”10

And now, even internationally renowned guru Deepak Chopra and famed author and speaker Tony Robbins are getting in on the booming market.11

Why? Because they know that the healing power of psychedelics could disrupt the $2.5 trillion mental health economy.12

Chopra even recently created a video where he discussed mental health and longevity and how psychedelic treatments like those offered by Cybin could impact both positively. 

As a result of all that is happening, many experts believe the psychedelic breakthrough is an exciting opportunity for investors.

Why? Because this market is predicted to hit $10 billion by 2027.13

If you consider this ground floor opportunity right now, it could be like investing in Pfizer.

Investing in Pfizer in 2012 could have tripled your money!

Except this time, some people are expecting better performance because psychedelics could be far more disruptive than anything in the health space.

Studies have proven that psychedelic-assisted therapy is up to…

“4x times more effective than anything else out there”

… in treating depression, PTSD, anxiety, addictions, and other mental health problems.

It could heal the underlying cause without the side-effects everyone knows SSRI and Prozac have.

Behind the scenes, scientists have been trying to harness psychedelics’ healing power for decades as a substitute.

It’s because pills such as Prozac and SSRIs only treat the symptoms.

After all, there must be a reason why TRILLIONS14 of dollars are continuously being spent in the mental health field, and yet…

900 million people continue to suffer.15

But now that scientists have finally cracked the code of psychedelics’ medicinal use, regulators like FDA and Health Canada have recently approved them for therapeutic purposes.

Psychedelics Got The Thumbs Up From The FDA & Health Canada

As a result of the underserved nature of the mental health market, this new industry is expected to DOUBLE16 by 2026, which means…

Even a small stake in Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) can make an impact.

This vast potential for financial gains is why Kevin O’ Leary prefers investing in psychedelics over cannabis.17

And it’s why PayPal founder Peter Thiel, the first investor in Facebook, is also all-in on this industry.18

Reason #2 – Markets Love a Breakthrough - & a Big One Could be Coming Soon for Psychedelics!

The Kernel – Cybin partnership that we mentioned earlier could soon produce study results that have a massive effect on this market. That means this is a unique opportunity for fast-acting investors.

Instead of promises of future action, Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) has an important trial underway now! This is a trial that features next-generation Kernel technology, real human subjects, and results that will be released shortly.

In fact, Cybin announced on March 31 the first study visit had been conducted in its feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics.19

Cybin understands the only way to achieve a real scientific breakthrough is to quantify the results of the treatment. That’s why Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) has gone one step further than competitors by using one of the most advanced instruments, called Kernel Flow:

Kernel Flow is a wearable headset that measures brain activity by recording local changes in blood oxygenation.

And when you combine this tech with proven therapies, you’ll be able to measure where the psychedelic molecules are working in real-time and calibrate treatments accordingly.

This means every step of the therapy is responsible for patient safety and future improvements, making it more marketable.

And because of Cybin’s (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) long-term thinking, it has also developed EMBARK, a psychedelic-assisted therapy model, which enables the company to build out its distribution ahead of time.

Cybin is leveraging Kernel’s Flow neuroimaging device to quantify brain activity during psychedelic experiences in real time, adding an exciting dimension to its investigative work focused on developing breakthrough therapeutics for mental health disorders.

Here’s why this could be just as important as focusing on the substance:

By developing a proprietary treatment model Cybin could use to train clinics, the company is establishing itself as the authority in upstream distribution.

And once that happens, it will only be natural for clinics everywhere to decide that Cybin is the best source of psychedelic molecules.

Any way you look at Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN), whether it’s through its 50+ patented molecules, its technology, or its proprietary treatment, the company is building ultimate certainty not just in this field, but also for its own brand.

It is because of this simple yet so far unchallenged philosophy that Cybin is poised to dominate the market.

Reason #3 - Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) Is One of The Only Psychedelic Companies With A Secure Patent Portfolio

While many psychedelic companies are approved for research, few have developed new psychedelic-derived compounds capable of obtaining Intellectual Property rights.

This capability is huge because it’s what Big Pharma looks for in an acquisition.

Not only has Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) secured over 10 psychedelic patents, but its team also brought FDA-approved medications such as Allegra, Sabril, Anzement, Vaniqa, Zyprexa, Cymbatta, Neuropro, and Vimpat to the market.

This is perhaps why Cybin won the “Psychedelic Company Of The Year” award in 2021.

And it’s why mainstream media like Times, Nasdaq, Forbes, Business Insider, and IBT have covered it.

The Media Is Abuzz With Conversations About This Stock

But this is no surprise because, collectively, the team members have experience developing some of the most widely used medicine, such as Allegra, Sabril, Anzemet, Vaniqa, Zyprexa, Cymbalta, Neupro, and Vimpat.

Truth is, Cybin’s unmatched ability to develop patent-protected treatments is part of the reason it is one of the most exciting stocks in this space.

You could, indeed, be well-positioned if you consider it now.

But like any great investment, there is a limited window of opportunity.

You see, right now, most people don’t have a clue about the upcoming psychedelic boom.

But when Cybin’s amazing breakthrough started to impact MILLIONS of lives, eliminating mental health problems everywhere…

People will find out about it, and its stock potential could maximize.

Reason #4 - Cybin's (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) Proprietary Product Differentiation

When it comes to psychedelic investing, it’s not necessarily about picking the first mover.

Several companies “ahead” in terms of getting research approval and commercialization, most of them are rushing ahead with no long-term advantage.

Why? Because they promote mostly raw use of psychedelics, there is no real product differentiation.

So no matter how “fast” they are, they could eventually reach a ceiling.

However, Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) is unique.

By having vigorously conducted over 150 clinical trials in a year (not even Big Pharma does this)…

It has chemically engineered 50+ proprietary psychedelic-based molecules that are all patent protected.

CYB003 is one of the noteworthy molecules — Cybin’s current “flagship product,” if you will.

And it’s perhaps the biggest breakthrough in this new industry.

Here’s why: When you ingest raw psilocybin mushrooms, it takes a while to feel their effects, and once they kick in, the effects last as long as 8 – 10 hours.

It would be hard to fit such a time commitment into both patients’ and treatment schedules, so it wouldn’t be scalable from a business standpoint.

That’s a fairly lengthy time commitment, so it wouldn’t be scalable from a business standpoint.

What’s worse, raw psychedelics have inconsistent and unpredictable effects on different people.

And that’s a tough sell because people want certainty with things they put in their bodies, which is exactly what CYB003 offers.

This proprietary molecule kicks in 2x faster and has half the duration of its raw form.

This means it’s very scalable for treatments. Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) took a big step forward to making those treatments reality when it announced the submission of an Investigational New Drug (IND) application to the US FDA for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (MDD).

Cybin’s Phase 1/2a trial, which is a randomized, double blind, placebo-controlled study, will evaluate people with moderate to severe MDD. The study will also evaluate the benefit of more than one administration and will provide pharmacokinetic and safety data. The trial design will allow for people to continue their treatment with selective serotonin reuptake inhibitors (SSRIs).

Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) has multiple provisional patents across 3 patent families covering new chemical entities, proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

International patent application brings the potential to obtain patent coverage in 153 countries.

Cybin is on an aggressive path to attain strategic patents and was just granted its first patent in early 2022 from the US Patent and Trademark Office for its investigational deuterated N,N-Dimethyltryptamine compound CYB004.

Plus, the results of different patients have been proven to be far more consistent and predictable, which gives everyone involved peace of mind.

The bottom line is, Cybin’s molecules are at the forefront of transforming millions of lives in a far more palatable way than its competitors.

It is the only company that is removing all the risks of psychedelics while keeping its benefits this way.

Now, unless you’re a psychedelic expert, you won’t hear information like this anywhere else. Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) is miles ahead of the competition.

And thankfully, you don’t need to know chemistry to profit from this revolution.

All you need to know is this: Whether in the form of pills, treatments, or other associated costs, TRILLIONS are being spent on mental health annually.20

Considering psychedelics could uproot the REAL causes of mental health, it’s easy to see why a trillion-dollar disruption is coming.

And the investors who position themselves early with a long-term winner could potentially enjoy a great ride.

Reason #5 - Cybin's (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) Exceptional Team With Big Pharma & FDA Background

Cybin’s leaders have deep backgrounds in psychedelics, pharmaceuticals, and research, and many of them are from Big Pharma like Merck, Teva, Sanofi, and others.

CYBN’s team hails from a premier Big Pharma background
with hundreds of years of clinical experience combined

Besides having experience building molecules in a way that gets patent-protected, these business veterans have a total of 37+ exits between them.

We’re not just talking about building 1, 2, or 3 successful businesses, but dozens!

And throughout the years, Cybin’s (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) team has…

  • Developed FDA-approved medications such as Allegra, Sabril, Anzement, Vaniqa, Zyprexa, Cymbatta, Neuropro, and Vimpat.
  • 300+ combined peer-reviewed publications by scientific leadership.
  • And overseen 60+ IND programs with the FDA (the first steps of getting a new medication to market.)

In a nutshell: These bigwigs know exactly how to build molecules that get patent protected and how to unlock their highest market value, which led to 37+ exits.

So, what are the chances Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) will experience the kind of growth investors would love to be a part of?

In addition to former Big Pharma execs, the company has other members like…

  • Eric Hoskins, the former Health Minister of Ontario.
  • Theresa Firestone, the former head of Pfizer Asia, and…
  • Thomas Laughren, the former Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA

Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) has insiders from these backgrounds to help it navigate regulatory environments and speed up medication commercialization

Reason #6 – Cybin's (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) World-Class Partnerships Help Accelerate Its Growth

Experience has shown you can evaluate a company based on the alliances it forms.

That’s why Cybin has partnered with the University of Washington.

Together, they launched a trial to treat depression, anxiety, burnout, and PTSD in doctors, nurses, and healthcare workers.

But Cybin isn’t limited to joining forces with just one science powerhouse.

The company has also partnered with Greenbrook TMS21, which has helped over 20,000 patients with depression22, to establish Mental Health Centers of Excellence that will facilitate R&D.

As a result, Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) will also be able to accelerate its study programs with faster and easier access to resources, which is another competitive advantage it has.

And as Cybin continues to gain momentum, it could attract more partnerships that will bolster its growth.

Reason #7 - Leadership Team Has Proven Experience In Building Successful Businesses

Doug Drysdale
CEO

  • 30+ years of experience in the healthcare sector.
  • Chaired the board of directors of a NASDAQ-listed company and, as a CEO for the past 14 years, has built and turned around 4 pharmaceutical companies.
  • Completed 16 corporate acquisitions across three continents and has raised $4 billion of both public and private capital.
  • Former Head of M&A at Actavis Group (Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion).

Aaron Bartlone
COO

  • Former President at UCB, Inc leading US commercial operations through the restructuring into CNS and Immunology Business Units with annualized 27% P&L growth ($2.2B in revenue).

Alex Nivorozhkin
Chief Scientific Officer

  • Lead NCE inventor of multiple successfully partnered medicine discovery and development programs. Seasoned medicinal chemist, medicine delivery expert and founder of multiple biotech companies.

Mike Palfreyman
Chief R&D Officer

  • 30 years of preclinical/clinical development experience: Scriptgen, EnVivo Pharma, Sanofi, GSK, Amorsa Therapeutics, and others.

Amir Inamdar
MBBS, DNB (Psych), MFPM - Chief Medical Officer

  • Qualified psychiatrist and pharmaceutical physician with over 20 years of clinical and medicine development experience.
  • Successfully progressed numerous candidate medications through preclinical development and early phase clinical trials to proof-of-concept studies
  • Experienced in leading global teams overseeing the development of novel medications across a range of psychiatric indications including treatment-resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder, and substance use disorders.

Alex Belser
Chief Clinical Officer

  • Licensed psychologist, clinical supervisor, and psychedelic researcher at Yale in psilocybin clinical trials. Research featured on the front page of the NYT, in the Atlantic, the New Yorker, The Guardian, VICE, and in Michael Pollan’s book, How to Change Your Mind.

RECAP: 7 Reasons

“Smart Money” Could Keep Pouring Into CYBN (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN)

  1. The Psychedelic Medicine Market Has Reached an “Inflection Point” (one industry report predicts a $10 billion market by 2027, another says it could double by 2026!).
  2. Cybin Is One of the Only Psychedelic Companies With A Secure Patent Portfolio (the company has IP developing capability like no others which Big Pharma gets attracted to). Its CYB003 just became the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder.
  3. Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) Has Created A Safer & More Scalable Approach To This Golden Era Of Psychedelics (all 50+ proprietary psychedelics molecules are engineered with practicality, profitability, and scalability in mind – this is the company’s biggest advantage!).
  4. Cybin’s Exceptional Team With Big Pharma & FDA Backgrounds (the team has deep expertise in bringing medicines to market, as well as political and regulatory insiders in their corner).
  5. Cybin (NYSEAMERICAN:CYBN) (NEO:CYBN)(NYSEAMERICAN:CYBN) (NEO:CYBN) Maximizes The Potential Of Science To Dominate The Market (it uses technology and strategies outside of medication development to build certainty in parties involved while securing future revenue streams).
  6. Cybin’s World-Class Partnerships Help Accelerate Its Growth (the company partners with established mental health authorities to further scientific development so it keeps its competitive advantage).
  7. CYBN’s Leadership Team Has Proven Experience In Building Successful Businesses (the team comprises of people with superb track records in business and the scientific community).

1 https://thedalesreport.com/psychedelics/study-shows-psilocybin-assisted-therapy-4-times-more-effective-than-typical-antidepressants/
2 https://www.fcf.de/blog/psychedelics-attract-more-vc-investments/
3 https://neuralink.com/
4 https://www.prnewswire.com/news-releases/the-chopra-foundation-announces-partnership-with-cybin-inc-to-increase-education-and-awareness-of-the-potential-use-of-psychedelics-in-supporting-well-being-and-mental-health-301482059.html
5 https://www.forbes.com/sites/javierhasse/2022/02/15/psychedelics-deepak-chopra-blackrock-and-tony-robins-is-cybin-the-hottest-mental-health-stock-right-now/?sh=517b5f285a57
6 https://www.forbes.com/sites/alanjbrochstein/2018/05/28/american-cannabis-stocks-offer-compelling-relative-value/?sh=6d5bdfdc588f
7 https://www.businesswire.com/news/home/20210803005698/en/Cybin-Announces-Closing-of-Overnight-Marketed-Public-Offering-of-Common-Shares-and-Exercise-of-Over-Allotment-Option
8 https://psychedelicstockwatch.com/psychedelic-stock-news/cybin-inc-reports-third-quarter-financial-results-and-recent-business-highlights
9 https://www.businesswire.com/news/home/20220218005087/en/Cybin-Announces-Additional-Adelia-Milestone-Achievement
10 https://tinyurl.com/7dvt8w59
11 https://www.forbes.com/sites/javierhasse/2022/02/15/psychedelics-deepak-chopra-blackrock-and-tony-robins-is-cybin-the-hottest-mental-health-stock-right-now/?sh=7d00f2f95a57
12 https://www.barchart.com/story/news/2513001/psychedelics-could-alter-a-potential-25-trillion-mental-health-market
13 https://tinyurl.com/57rr9upk
14 Slide 8
15 Slide 8
16https://psychedelicspotlight.com/global-psychedelic-market-worth-double-by-2026/
17 https://midasletter.com/2021/09/why-kevin-oleary-chose-psychedelics-over-cannabis-mindmed-mnmd-compass-pathways-cmps/
18 https://psychedelicspotlight.com/wall-street-psychedelics-stocks-investing-psychedelic-medicine-sector/
19 https://ir.cybin.com/investors/news/news-details/2022/Cybin-Announces-Initiation-of-Kernel-Flow-Feasibility-Study-Measuring-Psychedelic-Effects-on-the-Brain/default.aspx
20 Slide 8
21 https://ir.cybin.com/investors/news/news-details/2021/Cybin-Enters-into-Collaboration-Agreement-with-Greenbrook-TMS-to-Establish-Mental-Health-Centers-of-Excellence/default.aspx
22 https://www.google.com/search?q=greenbook+tms&oq=greenbook&aqs=chrome.0.69i59j46i433i512j0i10i512l2j0i512j0i10i512j0i512j0i10i512l2.5461j0j4&sourceid=chrome&ie=UTF-8

 

IMPORTANT NOTICE AND DISCLAIMER

This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Cybin Inc. (“CYBN”) and its securities, CYBN has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by CYBN) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP.

The Publisher does not own any shares of any profiled company CYBN and has no information concerning share ownership by others of in the profiled company CYBN. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

FORWARD LOOKING STATEMENTS.

This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to CYBN industry; (b) market opportunity; (c) CYBN business plans and strategies; (d) services that CYBN intends to offer; (e) CYBN milestone projections and targets; (f) CYBN expectations regarding receipt of approval for regulatory applications; (g) CYBN intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) CYBN expectations with regarding its ability to deCYBNr shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute CYBN business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) CYBN ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) CYBN ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) CYBN ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of CYBN to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) CYBN operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact CYBN business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing CYBN business operations (e) CYBN may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

INDEMNIFICATION/RELEASE OF LIABILITY.

By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

INTELLECTUAL PROPERTY.

Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

IMPORTANT NOTICE AND DISCLAIMER

This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:

  • The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Cybin Inc.

SHARE OWNERSHIP

The Website Host does not own any shares of any profiled Cybin Inc. and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

NO SECURITIES OFFERED

The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Cybin Inc. or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Cybin Inc. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Cybin Inc.’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

LINKS TO THIRD PARTY WEBSITES

This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.

INTELLECTUAL PROPERTY

The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.

FORWARD LOOKING INFORMATION

This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Cybin Inc. future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Cybin Inc. industry; (b) market opportunity; (c) Cybin Inc. business plans and strategies; (d) services that Cybin Inc. intends to offer; (e) Cybin Inc. milestone projections and targets; (f) Cybin Inc. expectations regarding receipt of approval for regulatory applications; (g) Cybin Inc. intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Cybin Inc. expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Cybin Inc. business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Cybin Inc. ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Cybin Inc. ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Cybin Inc. ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Cybin Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Cybin Inc. operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Cybin Inc. business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Cybin Inc. business operations (e) Cybin Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

HISTORICAL INFORMATION

Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Cybin Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Cybin Inc. or such entities and are not necessarily indicative of future performance of Cybin Inc. or such entities.